A5044834386- Alzheimer's disease research and treatments
- Dementia and Cognitive Impairment Research
- Amyotrophic Lateral Sclerosis Research
- Neuroinflammation and Neurodegeneration Mechanisms
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Bioinformatics and Genomic Networks
- Parkinson's Disease Mechanisms and Treatments
- S100 Proteins and Annexins
- Neurological Disorders and Treatments
- Cholinesterase and Neurodegenerative Diseases
- Genetics and Neurodevelopmental Disorders
- Folate and B Vitamins Research
- Neurological Disease Mechanisms and Treatments
- Tryptophan and brain disorders
- 14-3-3 protein interactions
- Metabolomics and Mass Spectrometry Studies
- Health, Environment, Cognitive Aging
- Amino Acid Enzymes and Metabolism
- Studies on Chitinases and Chitosanases
- Peptidase Inhibition and Analysis
- Bipolar Disorder and Treatment
- Diet and metabolism studies
- Cerebrovascular and Carotid Artery Diseases
- Cancer-related cognitive impairment studies
- Mitochondrial Function and Pathology
Universidad San Pablo CEU
2020-2025
Pasqual Maragall Foundation
2023-2025
Barcelonaβeta Brain Research Center
2023-2025
Hospital Del Mar
2023-2025
Brain (Germany)
2025
Amsterdam University Medical Centers
2018-2024
Amsterdam Neuroscience
2014-2024
Vrije Universiteit Amsterdam
2018-2024
University of Pennsylvania
2024
Universidad San Pablo
2022-2024
To examine the clinical value of neurofilament light chain (NfL) and phospho-tau/total tau ratio (p/t-tau) across entire frontotemporal dementia (FTD) spectrum in a large, well-defined cohort.CSF NfL p/t-tau levels were studied 361 patients with FTD: 179 behavioral variant FTD, 17 FTD motor neuron disease (FTD-MND), 36 semantic primary progressive aphasia (PPA), 19 nonfluent PPA, 4 logopenic PPA (lvPPA), 42 corticobasal syndrome, 64 supranuclear palsy. Forty-five cognitively healthy controls...
Diagnosis of dementia with Lewy bodies (DLB) is challenging and specific biofluid biomarkers are highly needed. We employed proximity extension-based assays to measure 665 proteins in the cerebrospinal fluid (CSF) from patients DLB (n = 109), Alzheimer´s disease (AD, n 235) cognitively unimpaired controls 190). identified over 50 CSF dysregulated DLB, enriched myelination processes among others. The dopamine biosynthesis enzyme DDC was strongest protein, could efficiently discriminate AD...
Autosomal dominant Alzheimer's disease (ADAD) offers a unique opportunity to study pathophysiological changes in relatively young population with few comorbidities. A comprehensive investigation of proteome occurring ADAD could provide valuable insights into AD-related biological mechanisms and uncover novel biomarkers therapeutic targets. Furthermore, might serve as model for sporadic AD, but in-depth comparisons are lacking. We aimed identify dysregulated CSF proteins determine the degree...
Abstract Background There is a need for novel fluid biomarkers tracking neuroinflammatory responses in Alzheimer’s disease (AD). Our recent cerebrospinal (CSF) proteomics study revealed that migration inhibitory factor (MIF) and soluble triggering receptor expressed on myeloid cells 1 (sTREM1) increased along the AD continuum. We aimed to assess potential use of these proteins, addition sTREM2, as CSF monitor inflammatory processes AD. Methods included cognitively unimpaired controls ( n =...
<h2>Summary</h2><h3>Background</h3> Neuroimaging-based brain-age delta has been shown to be a mediator linking cardiovascular risk factors cognitive function. We aimed assess the mediating role of in association between modifiable dementia and longitudinal decline middle-aged older individuals who are asymptomatic, stratified by Alzheimer's disease pathology. also explored whether mediation effect is specific domain. <h3>Methods</h3> In this cohort study, we included participants from ALFA+...
To evaluate poly(GP), a dipeptide repeat protein, and neurofilament light chain (NfL) as biomarkers in presymptomatic C9orf72 expansion carriers patients with C9orf72-associated frontotemporal dementia. Additionally, to investigate the relationship of poly(GP) indicators neurodegeneration measured by NfL grey matter volume.We levels cerebrospinal fluid (CSF) from 25 carriers, 64 symptomatic dementia, 12 noncarriers. We explored associations volumes using region interest voxel-wise...
Alzheimer’s disease (AD) is the most common form of dementia and there no successful treatment available. Evidence suggests that fibril formation amyloid β-peptide (Aβ) a major underlying cause AD, strategies reduce toxic effects Aβ are sought for. The BRICHOS domain found in several proteins, including Bri2 (also called integral membrane protein 2B (ITM2B)), mutants which associated with neurodegeneration, Bri3 (ITM2C). We have used mouse hippocampal neurons brain tissues from mice humans...
Providing an accurate prognosis for individual dementia patients remains a challenge since they greatly differ in rates of cognitive decline. In this study, we used machine learning techniques with the aim to identify cerebrospinal fluid (CSF) biomarkers that predict rate decline within patients. First, longitudinal mini-mental state examination scores (MMSE) 210 were create fast and slow progression groups. Second, trained random forest classifiers on CSF proteomic profiles obtained...
To prospectively determine the diagnostic value of cerebrospinal fluid (CSF) levels total-tau (tau) to amyloid-β1-42 ratio (Aβ1-42) (tau/Aβ1-42 ratio), phosphorylated-tau (p-tau) tau (p-tau/tau neurofilament light chain (NfL) and YKL40 in late-onset frontal lobe syndrome, particular for differential diagnosis behavioral variant frontotemporal dementia (bvFTD) versus primary psychiatric disorders (PSY).We included patients with a multidisciplinary 2-year-follow-up probable/definite bvFTD (n =...
Blood-based biomarkers for Alzheimer's disease (AD) have been widely studied, but direct comparisons of several in clinical settings remain limited. In this cross-sectional study, plasma from 197 participants the BIODEGMAR cohort (Hospital del Mar, Barcelona) were analyzed. Participants classified based on AD cerebrospinal fluid (CSF) core biomarkers. We assessed ability p-tau181, p-tau217, p-tau231, t-tau, and Aβ42/40 to classify Aβ pathology status. Plasma p-tau had a greater diagnostic...
<title>Abstract</title> Plasma biomarkers are emerging as noninvasive tools to detect neurodegenerative diseases and monitor treatments in clinical trials. The bPRIDE study investigates blood-based improve the differential diagnosis molecular staging of Alzheimer's disease (AD), dementia with Lewy bodies (DLB), frontotemporal (FTD). Using proximity extension assay proteomics, we analyzed n=1319 plasma samples from 6 well-characterized cohorts. More than 200 proteins were found dysregulated...
Abstract Many Alzheimer’s disease (AD) genes including Apolipoprotein E ( APOE ) are found to be expressed in blood-derived macrophages and thus may alter blood protein levels. We measured 91 neuro-proteins plasma from 316 participants of the Rotterdam Study (incident AD = 161) using Proximity Extension Ligation assay. studied association proteins with overall sample stratified by . Findings study were replicated 186 patients BioFINDER study. further evaluated correlation these biomarkers...
Aggregates of the microtubule-associated protein tau are a common marker neurodegenerative diseases collectively termed as tauopathies, such Alzheimer's disease (AD) and frontotemporal dementia. Therapeutic strategies based on have failed in late stage clinical trials, suggesting that tauopathy may be consequence upstream causal mechanisms. As increasing levels reactive oxygen species (ROS) trigger aggregation or modulate degradation and, we had previously shown ROS producing enzyme NADPH...
Our previous antibody-based cerebrospinal fluid (CSF) proteomics study showed that Thimet oligopeptidase (THOP1), an amyloid beta (Aβ) neuropeptidase, was increased in mild cognitive impairment with pathology (MCI-Aβ+) and Alzheimer's disease (AD) dementia compared controls Lewy bodies (DLB), highlighting the potential of CSF THOP1 as early specific biomarker for AD. We aimed to develop immunoassays large-scale analysis validate our findings two independent cohorts.